[{"address1": "The MediaWorks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 399, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 59, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 2737804, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 51, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 58, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 67, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 57, "title": "Senior VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edgar E. W. Braendle M.D., Ph.D.", "age": 63, "title": "Senior VP & Chief Development Officer", "yearBorn": 1960, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chris  Williams", "age": 43, "title": "Senior Vice President of Corporate Development", "yearBorn": 1980, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "title": "Chief Human Resources Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.28, "open": 6.25, "dayLow": 5.94, "dayHigh": 6.685, "regularMarketPreviousClose": 6.28, "regularMarketOpen": 6.25, "regularMarketDayLow": 5.94, "regularMarketDayHigh": 6.685, "beta": 1.786, "forwardPE": -7.6494255, "volume": 1815353, "regularMarketVolume": 1815353, "averageVolume": 979867, "averageVolume10days": 1528320, "averageDailyVolume10Day": 1528320, "bid": 6.63, "ask": 6.64, "bidSize": 900, "askSize": 1100, "marketCap": 1157896832, "fiftyTwoWeekLow": 1.61, "fiftyTwoWeekHigh": 7.0, "priceToSalesTrailing12Months": 209.64998, "fiftyDayAverage": 4.5188, "twoHundredDayAverage": 3.0376, "currency": "USD", "enterpriseValue": 888366080, "floatShares": 51292221, "sharesOutstanding": 173988992, "sharesShort": 2651640, "sharesShortPriorMonth": 1483746, "sharesShortPreviousMonthDate": 1700006400, "dateShortInterest": 1702598400, "sharesPercentSharesOut": 0.0152, "heldPercentInsiders": 0.08404, "heldPercentInstitutions": 0.78317, "shortRatio": 2.17, "shortPercentOfFloat": 0.0327, "impliedSharesOutstanding": 173988992, "bookValue": 1.038, "priceToBook": 6.4113684, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -158163008, "trailingEps": -0.98, "forwardEps": -0.87, "enterpriseToRevenue": 160.848, "enterpriseToEbitda": -5.416, "52WeekChange": 2.488889, "SandP52WeekChange": 0.20686829, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AUTL", "underlyingSymbol": "AUTL", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "firstTradeDateEpochUtc": 1529674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "da5466ad-c9a9-3bae-a4e5-c7afee3582d0", "messageBoardId": "finmb_562879769", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.655, "targetHighPrice": 12.0, "targetLowPrice": 4.8, "targetMeanPrice": 9.08, "targetMedianPrice": 9.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 256415008, "totalCashPerShare": 1.474, "ebitda": -164040992, "totalDebt": 52458000, "quickRatio": 7.948, "currentRatio": 8.215, "totalRevenue": 5523000, "debtToEquity": 29.06, "revenuePerShare": 0.035, "returnOnAssets": -0.31797, "returnOnEquity": -0.92582, "grossProfits": -130860000, "freeCashflow": -116022872, "operatingCashflow": -135320000, "revenueGrowth": -0.829, "operatingMargins": -116.85222, "financialCurrency": "USD", "trailingPegRatio": null}]